Optune Lua and pemetrexed + cisplatin/carboplatin may help your patients with MPM live longer with no added chemotherapy-related side effects1
Optune Lua approval was based on the STELLAR trial: a phase II, prospective, pivotal, single-arm trial designed to study the safety and efficacy of Optune Lua and pemetrexed + cisplatin/carboplatin first-line in patients with unresectable, locally advanced or metastatic, MPM.2
No systemic AEs were considered to be related to the use of Optune Lua1
- The only AE attributed to the use of Optune Lua is the known skin irritation seen in 71% of patients in this study (66% mild to moderate and 5% severe)
References: 1. Optune Lua . Instructions for Use for Unresectable Malignant Pleural Mesothelioma. Novocure; 2019. 2. FDA Approves the NovoTTF-100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma [press release]. St. Helier, Jersey: Business Wire; May 23, 2019. 3. Hazarika M, White RM, Johnson JR, et al. FDA drug approval summaries: pemetrexed (Alimta®). The Oncologist. 2004;9(5):482-488. 4. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644.